Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
May Hagiwara, Sumeet Panjabi, Tom Delea, Emre Yucel & Rafael Fonseca. (2020) Burden of disease progression in patients with multiple myeloma in the US. Leukemia & Lymphoma 61:1, pages 47-55.
Read now
Read now
Evangelos Terpos, Aurelien Jamotte, Alexandra Christodoulopoulou, Marco Campioni, Debajyoti Bhowmik, Lisa Kennedy & Wolfgang Willenbacher. (2019) A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy. Journal of Medical Economics 22:8, pages 766-776.
Read now
Read now
Articles from other publishers (8)
Dionna Jacobson, Benoit Cadieux, Celestia S. Higano, David H. Henry, Basia A. Bachmann, Marko Rehn, Alison T. Stopeck & Hossam Saad. (2022) Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach. Journal of Bone Oncology 34, pages 100423.
Crossref
Crossref
Benoit Cadieux, Robert Coleman, Pegah Jafarinasabian, Allan Lipton, Robert Z. Orlowski, Fred Saad, Giorgio V. Scagliotti, Kazuyuki Shimizu & Alison Stopeck. (2022) Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval. Journal of Bone Oncology 33, pages 100416.
Crossref
Crossref
Rafael Fonseca, May Hagiwara, Sumeet Panjabi, Emre Yucel, Jacqueline Buchanan & Thomas Delea. (2021) Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US. Blood Cancer Journal 11:2.
Crossref
Crossref
Suying Li, Haifeng Guo, Yi Peng, Tingting Gong, Alan Fu, Debajyoti Bhowmik, Rohini K. Hernandez, Katherine B. Carlson, Kimberly A. Lowe, Jitesh Rana & Shuling Li. (2021) Discharge status and post-discharge healthcare costs after skeletal-related event hospitalizations among medicare patients with bone metastatic solid tumors or multiple myeloma. Journal of Bone Oncology 26, pages 100328.
Crossref
Crossref
María-Victoria Mateos, Leah Fink, Niranchana Koneswaran, Michele Intorcia, Christina Giannopoulou, Daniela Niepel & Michele Cavo. (2020) Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review. BMC Cancer 20:1.
Crossref
Crossref
Sikander Ailawadhi, Rohan Medhekar, Nicole Princic, Robert Fowler, Oth Tran, Debajyoti Bhowmik & Sumeet Panjabi. (2019) Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events. Journal of Oncology Pharmacy Practice 26:5, pages 1070-1079.
Crossref
Crossref
Alanna C Green, Darren Lath, Katie Hudson, Brant Walkley, Jennifer M Down, Robert Owen, Holly R Evans, Julia Paton‐Hough, Gwendolen C Reilly, Michelle A Lawson & Andrew D Chantry. (2019) TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model. Journal of Bone and Mineral Research 34:12, pages 2311-2326.
Crossref
Crossref
Daniel OravecOmar YaldoCarrie BoltonMichael J. FlynnMarnix van HolsbeeckYener N. Yeni. (2019) Digital Tomosynthesis and Fractal Analysis Predict Prevalent Vertebral Fractures in Patients With Multiple Myeloma: A Preliminary In Vivo Study. American Journal of Roentgenology 213:1, pages W38-W44.
Crossref
Crossref